P-048 - Novel treatment of locally advanced esophageal cancer

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Oesophageal Cancer
Presenter A. Taghizadeh
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors A. Taghizadeh, M. Fazl Ersi, A. Emadi
  • MUMS, Mashhad/IR

Abstract

Introduction

The aim of this pilot study was to evaluate the efficacy of induction chemotherapy plus concurrent chemoradiation with weekly Paclitaxel /carboplatin in Locally advanced squamous cell carcinoma (SCC) of the esophagus.

Methods

13 patients with Locally advanced squamous cell carcinoma (SCC) of the esophagus received induction chemotherapy with paclitaxel 50mg/m2 and carboplatin (auc = 2) for 4 weeks & then concurrent chemoradiation with 5040/180cgy in 5 weeks and same regimen of induction chemotherapy. After 4 to 6 weeks the patients refer to oncologic surgeon for R0 resection.

Results

13 patients with non-metastatic esophageal cancer were entered from Jan 2012 until Jan 2013. 46% of patients were male and 53% were female. The patients age range between 36-73 and all of them had Scc histology. CPR (complete pathologic response) was achieved in 10 (76%) of patients and partial response in 2 (15%) & near complete response in 1 (7%) of patients.

Conclusion

Preoperative induction plus concurrent chemoradiation with weekly Paclitaxel /carboplatin is a good option with improve PCR rate for Locally advanced squamous cell carcinoma (SCC) of the esophagus. Large trails are needed to confirm this study results.